Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

NCT05424003 on ClinicalTrials.gov · last registry update 2026-06-04

A small phase 2 — 50 participants, against a typical 110. Its estimated completion date, 1 August 2026, has passed with no update to the record. Primary outcome, as filed: Change in weight. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Virginia
Sponsor type: Other
Enrollment: 50
Started: 2024-02-22
Primary completion: 2026-08-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in weight

Conditions studied

NAFLD

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.